| Catalog Number |
301019021 |
| Medical Device Problem Code |
Break (1069)
|
| Health Effect - Clinical Code |
No Clinical Signs, Symptoms or Conditions (4582)
|
| Date of Event |
08/20/2023
|
|
Type of Reportable Event
|
Malfunction
|
|
Event or Problem Description
|
|
It was reported that on (b)(6) 2023, during spine procedure(t8-9 fusion) the 4.35 awl tip tap was being used in the case and the entire tip broke off inside of the patient.Added some time to case trying to get the piece out.They had to open universal removal and the shukla set to finally remove the broken piece, but the pedicle was destroyed.It increased potential risk of infection and the time under anesthesia.They also broke a removal driver in the process.Multiple x-rays were taken to confirm the full removal of the broken piece.Surgery was completed successfully with a delay of 60 minutes.This report is for one (1) 4.35 nav dual lead awl tip tap.This is report 1 of 2 for complaint (b)(4).
|
| |
|
Additional Manufacturer Narrative
|
|
Depuy synthes is submitting this report pursuant to the provisions of 21 cfr, part 803.This report may be based on information which depuy synthes has not been able to investigate or verify prior to the required reporting date.This report does not reflect a conclusion by fda, depuy synthes or its employees that the report constitutes an admission that the device, depuy synthes, or its employees caused or contributed to the potential event described in this report.If the information is unknown, not available or does not apply, the section/field of the form is left blank.D9: complainant part is not expected to be returned for manufacturer review/investigation.H3, h6: the investigation could not be completed; no conclusion could be drawn, as no product was received.Based on the information available, it has been determined that no corrective and/or preventative action is proposed.This complaint will be accounted for and monitored via post market surveillance activities.If additional information is made available, the investigation will be updated as applicable.Device was used for treatment, not diagnosis.If information is obtained that was not available for the initial medwatch, a follow-up medwatch will be filed as appropriate.
|
| |
|
Additional Manufacturer Narrative
|
|
Depuy synthes is submitting this report pursuant to the provisions of 21 cfr, part 803.This report may be based on information which depuy synthes has not been able to investigate or verify prior to the required reporting date.This report does not reflect a conclusion by fda, depuy synthes or its employees that the report constitutes an admission that the device, depuy synthes, or its employees caused or contributed to the potential event described in this report.If the information is unknown, not available or does not apply, the section/field of the form is left blank.A review of the receiving inspection (ri) for 4.35 nav dual lead awl tip tap was conducted identifying that lot number ng101223 released in one batch.Batch1: lot qty of (b)(4) units were released on nov 9, 2020 with no discrepancies.Supplier: ng instruments.As a result, the ri identified no issues during the manufacturing and release of this device that could have contributed to the problem reported by the customer.The photo was returned to depuy synthes for evaluation.The depuy synthes team conducted a visual inspection of the returned device from the photo.Visual analysis of the photo revealed that 4.35 nav dual lead awl tip tap had broken at the tip.As the device was not returned, an as-received condition could not be assessed, and a dimensional inspection and document/specification review were not completed.As part of depuy synthes quality process, all devices are manufactured, inspected, and released to approved specifications.The overall complaint was confirmed for 4.35 nav dual lead awl tip tap.There is no indication that a design or manufacturing issue has caused the complaint condition and hence the root cause cannot be determined.Based on the investigation findings, it has been determined that no corrective and/or preventative action is proposed.Additional monitoring for any potential safety signals will be conducted through complaint trending and other post-market safety surveillance activities.If information is obtained that was not available for this medwatch, a follow-up medwatch will be filed as appropriate.
|
| |
|
Search Alerts/Recalls
|
|